

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number
WO 02/074944 A1

(51) International Patent Classification⁷: C12N 9/12,
15/54, C12P 13/04, 13/08, C12N 1/21

(21) International Application Number: PCT/EP02/02830

(22) International Filing Date: 14 March 2002 (14.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
101 12 992.0 17 March 2001 (17.03.2001) DE

(71) Applicant: DEGUSSA AG [DE/DE]; Bennigsenplatz 1,
40474 Düsseldorf (DE).

(72) Inventors: FARWICK, Mike; Gustav-Adolf-Strasse 11,
33615 Bielefeld (DE). BATHE, Brigitte; Twieten 1, 33154
Salzkötten (DE). BREHME, Jennifer; Kastanienstrasse
10, 33649 Bielefeld (DE). HUTHMACHER, Klaus;
Lärchenweg 18, 63571 Gelnhausen (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN,
YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/074944 A1

(54) Title: PROCESS FOR THE PREPARATION OF L-AMINO ACIDS BY USING CORYNEFORM BACTERIA

(57) Abstract: The invention relates to a process for the preparation of L-amino acids, wherein the following steps are implemented: a) fermentation of the coryneform bacteria producing the desired L-amino acid, in which at least the gene coding for 6-phosphofructokinase and/or the gene coding for 1-phosphofructokinase are/is attenuated, b) enrichment of the desired L-amino acid in the medium or in the cells of the bacteria, and c) isolation of the L-amino acid, and optionally bacteria are employed in which, in addition, further genes of the biosynthetic pathway of the desired L-amino acid are enhanced, or bacteria are employed in which the metabolic pathways that diminish the formation of the desired L-amino acid are at least partly switched off.

**Process for the preparation of L-amino acids by using
coryneform bacteria**

Field of the Invention

5 The invention provides a process for the preparation of L-amino acids, in particular L-lysine, by using coryneform bacteria in which the pfkA gene coding for 6-phosphofructokinase and/or the pfkB gene coding for 1-phosphofructokinase are/is attenuated.

State of the Art

10 L-amino acids, in particular L-lysine, find application in human medicine and in the pharmaceutical industry, in the food industry and, quite especially, in animal nutrition.

It is known that amino acids are prepared by fermentation of strains of coryneform bacteria, in particular
15 *Corynebacterium glutamicum*. On account of its great importance, work on improving the production process is constantly in progress. Improvements to the process may concern measures pertaining to fermentation technology, such as, for example, stirring and provision with oxygen,
20 or the composition of the nutrient media, such as, for example, the sugar concentration during fermentation, or the reprocessing into product-form by, for example, ion-exchange chromatography, or the intrinsic output properties of the micro-organism itself.

25 With a view to improving the output properties of these micro-organisms, methods of mutagenesis, selection and mutant selection are adopted. In this way, strains are obtained that are resistant to antimetabolites such as, for example, the lysine analogue S-(2-aminoethyl)cysteine or
30 that are auxotrophic in respect of metabolites of regulatory significance and that produce L-amino acids.

Methods pertaining to recombinant DNA technology have also been employed for a number of years for the improvement of strains of *Corynebacterium glutamicum* producing L-amino acid, by individual amino-acid-biosynthesis genes being
5 amplified and by the effect on the production of L-amino acid being investigated.

Object of the Invention

The inventors have set themselves the task of making available new foundations for improved processes for the
10 fermentative preparation of L-amino acids, in particular L-lysine, by using coryneform bacteria.

Summary of the Invention

When mention is made in the following of L-amino acids or amino acids, these expressions are intended to mean one or
15 more amino acids, including their salts, selected from the group comprising L-asparagine, L-threonine, L-serine, L-glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L-methionine, L-isoleucine, L-leucine, L-tyrosine, L-phenylalanine, L-histidine, L-lysine, L-tryptophan and L-
20 arginine. L-lysine is particularly preferred.

When mention is made in the following of L-lysine or lysine, these expressions are intended to mean not only the bases but also the salts such as, for example, lysine monohydrochloride or lysine sulfate.

25 The invention provides a process for the fermentative preparation of L-amino acids by using coryneform bacteria in which at least the nucleotide sequence coding for 6-phosphofructokinase and/or the nucleotide sequence coding for 1-phosphofructokinase are/is attenuated, in particular
30 switched off or expressed at a low level.

This invention further provides a process for the fermentative preparation of L-amino acids in which the following steps are implemented:

- 5 a) fermentation of the coryneform bacteria producing the L-amino acid, in which at least the nucleotide sequence coding for 6-phosphofructokinase and/or the nucleotide sequence coding for 1-phosphofructokinase are/is attenuated, in particular switched off or expressed at a low level;
- 10 b) enrichment of the L-amino acids in the medium or in the cells of the bacteria; and
- c) isolation of the desired L-amino acids, whereby constituents of the fermentation broth and/or of the biomass optionally remain in the end product in
15 proportions or in their total quantities.

Detailed Description of the Invention

The strains that are employed preferably already produce L-amino acids, in particular L-lysine, before the attenuation of the pfkA gene coding for 6-phosphofructokinase and/or of
20 the pfkB gene coding for 1-phosphofructokinase.

Preferred embodiments are to be found in the Claims.

The term 'attenuation' in this context describes the diminution or switching-off of the intracellular activity of one or more enzymes (proteins) in a micro-organism that
25 are coded by the corresponding DNA, by use being made, for example, of a weak promoter or by use being made of a gene or allele that codes for a corresponding enzyme with a low activity or that inactivates the corresponding gene or enzyme (protein) and by these measures optionally being
30 combined.

By virtue of the measures of attenuation, the activity or concentration of the corresponding protein is lowered in general to 0 to 75%, 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% of the activity or concentration of the wild-type protein or of the activity or concentration of the protein in the initial micro-organism.

The micro-organisms that are the subject-matter of the present invention are able to produce amino acids from glucose, saccharose, lactose, fructose, maltose, molasses, starch, cellulose or from glycerin and ethanol. It may be a question of representatives of coryneform bacteria, in particular of the genus *Corynebacterium*. In the case of the genus *Corynebacterium*, in particular the species *Corynebacterium glutamicum* should be mentioned, which is known amongst experts for its ability to produce L-amino acids.

Suitable strains of the genus *Corynebacterium*, in particular of the species *Corynebacterium glutamicum*, are especially the known wild-type strains

Corynebacterium glutamicum ATCC13032
Corynebacterium acetoglutamicum ATCC15806
Corynebacterium acetoacidophilum ATCC13870
Corynebacterium melassecola ATCC17965
Corynebacterium thermoaminogenes FERM BP-1539
Brevibacterium flavum ATCC14067
Brevibacterium lactofermentum ATCC13869 and
Brevibacterium divaricatum ATCC14020

and mutants and strains prepared therefrom that produce L-amino acids,

such as, for example, the L-lysine-producing strains

Corynebacterium glutamicum FERM-P 1709

Brevibacterium flavum FERM-P 1708

Brevibacterium lactofermentum FERM-P 1712

5 *Corynebacterium glutamicum* FERM-P 6463

Corynebacterium glutamicum FERM-P 6464 and

Corynebacterium glutamicum DSM 5715.

10 It has been found that coryneform bacteria produce L-amino acids in improved manner after attenuation of the gene coding for 6-phosphofructokinase (EC: 2.7.1.11) and/or of the gene coding for 1-phosphofructokinase (EC 2.7.1.56).

15 The nucleotide sequence of the gene coding for 6-phosphofructokinase of *Corynebacterium glutamicum* can be gathered from patent application WO 01/00844 under Identification Code RXA00206 as SEQ ID No. 53.

The nucleotide sequence of the gene coding for 1-phosphofructokinase of *Corynebacterium glutamicum* can be gathered from patent application WO 01/00844 under Identification Code RXA01882 as SEQ ID No. 57.

20 The nucleotide sequences are also deposited in the gene bank under Accession Numbers AX064927 and AX064931, respectively.

25 The claimed nucleotide sequences of the genes coding for 1-phosphofructokinase and for 6-phosphofructokinase, represented in SEQ ID No. 3 and SEQ ID No. 1, respectively, are elongated in comparison with the sequences known from the state of the art by, in each instance, preferably up to 700 base-pairs in front of the start codon and behind the stop codon of the gene.

The elongations in comparison with the sequence known from the state of the art consist in SEQ ID No. 3 of the base-pairs 1 to 508 and 1684 to 2234, respectively.

5 In SEQ ID No. 1 the elongations in comparison with the sequence known from the state of the art consist of the base-pairs 1 to 531 and 1621 to 2160, respectively.

The amino-acid sequences of the associated gene products are represented in SEQ ID No. 4 and SEQ ID No. 2, respectively.

10 It has been found that processes for attenuation that are known as such can be employed particularly successfully with the aid of the elongated sequences that are made available in this way.

Such a process is the method of gene replacement. With
15 this method, a mutation such as, for example, a deletion, an insertion or base-exchange in the gene of interest is produced in vitro. The allele that is produced is, in turn, cloned into a vector that is non-replicative in respect of *C. glutamicum* and said vector is subsequently
20 converted by transformation or conjugation into the desired host of *C. glutamicum*. After homologous recombination by means of a first cross-over event bringing about integration and by means of a suitable second cross-over event in the target gene or in the target sequence bringing
25 about an excision, the incorporation of the mutation or of the allele is obtained. This method was used in EP: 00110021.3, for example, in order to switch off the *secG* gene of *C. glutamicum*.

The elongation of the sequences that are employed is not
30 restricted to 600 base-pairs in front of the start codon and behind the stop codon. It preferably lies within the range from 300 to 700 base-pairs, but it may also amount to

up to 800 base-pairs. The elongations may also contain different quantities of base-pairs.

The sequences, described in the stated passages, coding for 6-phosphofructokinase or 1-phosphofructokinase can be used in accordance with the invention. Moreover, use can be made of alleles of 6-phosphofructokinase or 1-phosphofructokinase that arise from the degenerate nature of the genetic code or as a result of functionally neutral sense mutations.

- 10 With a view to achieving an attenuation, either the expression of the gene coding for 6-phosphofructokinase and/or of the gene coding for 1-phosphofructokinase or the catalytic properties of the gene products can be lowered or switched off. Both measures are optionally combined.
- 15 The gene expression can be reduced by suitable culturing or by genetic modification (mutation) of the signal structures of gene expression. Signal structures of gene expression are, for example, repressor genes, activator genes, operators, promoters, attenuators, ribosome binding sites, the start codon and terminators. Data relating to this can be found by a person skilled in the art in, for example, patent application WO 96/15246, in Boyd and Murphy (Journal of Bacteriology 170: 5949 (1988)), in Voskuil and Chambliss (Nucleic Acids Research 26: 3548 (1998)), in Jensen and Hammer (Biotechnology and Bioengineering 58: 191 (1998)), in Pátek et al. (Microbiology 142: 1297 (1996)) and in known textbooks on genetics and molecular biology such as, for example, the textbook by Knippers (*Molekulare Genetik*, 6th Edition, Georg Thieme Verlag, Stuttgart, Germany, 1995) or in that by Winnacker (*Gene und Klone*, VCH Verlagsgesellschaft, Weinheim, Germany, 1990).
- 30

Mutations that lead to a change in or a lowering of the catalytic properties of enzyme proteins are known from the state of the art; by way of examples, mention may be made

of the papers by Qiu and Goodman (Journal of Biological Chemistry 272: 8611-8617 (1997)), Sugimoto et al.

(Bioscience Biotechnology and Biochemistry 61: 1760-1762 (1997)) and Möckel (*Die Threonindehydratase aus*

- 5 *Corynebacterium glutamicum: Aufhebung der allosterischen Regulation und Struktur des Enzyms*, Berichte des Forschungszentrums Jülichs, Jül-2906, ISSN09442952, Jülich, Germany, 1994). Synoptic accounts can be gathered from known textbooks on genetics and molecular biology such as,
10 for example, that by Hagemann (*Allgemeine Genetik*, Gustav Fischer Verlag, Stuttgart, 1986).

- Transitions, transversions, insertions and deletions enter into consideration by way of mutations. Depending on the effect of the amino-acid exchange on the enzyme activity,
15 one speaks of missense mutations or nonsense mutations. Insertions or deletions of at least one base-pair in a gene lead to frame-shift mutations, as a consequence of which false amino acids are incorporated or the translation terminates prematurely. Deletions of several codons
20 typically lead to a complete loss of enzyme activity. Instructions for the generation of mutations of such a type pertain to the state of the art and can be gathered from known textbooks on genetics and molecular biology such as,
for example, the textbook by Knippers (*Molekulare Genetik*,
25 6th Edition, Georg Thieme Verlag, Stuttgart, Germany, 1995), that by Winnacker (*Gene und Klone*, VCH Verlagsgesellschaft, Weinheim, Germany, 1990) or that by Hagemann (*Allgemeine Genetik*, Gustav Fischer Verlag, Stuttgart, 1986).

- 30 Customary methods for mutating genes of *C. glutamicum* are the methods of gene disruption and of gene replacement described by Schwarzer and Pühler (*Bio/Technology* 9, 84-87 (1991)).

- In the case of the method of gene disruption, a central
35 part of the coding region of the gene of interest is cloned

into a plasmid vector that is able to replicate in a host (typically *E. coli*) but not in *C. glutamicum*. By way of vectors, pSUP301 (Simon et al., Bio/Technology 1, 784-791 (1983)), pK18mob or pK19mob (Schäfer et al., Gene 145, 69-73 (1994)), pK18mobsacB or pK19mobsacB (Jäger et al., Journal of Bacteriology 174: 5462-65 (1992)), pGEM-T (Promega corporation, Madison, WI, USA), pCR2.1-TOPO (Shuman (1994), Journal of Biological Chemistry 269:32678-84; US Patent 5,487,993), pCR@Blunt (Invitrogen, Groningen, Netherlands; Bernard et al., Journal of Molecular Biology, 234: 534-541 (1993)) or pEM1 (Schrumpf et al, 1991, Journal of Bacteriology 173:4510-4516), for example, enter into consideration. The plasmid vector, which contains the central part of the coding region of the gene, is subsequently converted by conjugation or transformation into the desired strain of *C. glutamicum*. The method of conjugation is described, for example, in Schäfer et al. (Applied and Environmental Microbiology 60, 756-759 (1994)). Methods for transformation are described, for example, in Thierbach et al. (Applied Microbiology and Biotechnology 29, 356-362 (1988)), Dunican and Shivnan (Bio/Technology 7, 1067-1070 (1989)) and Tauch et al. (FEMS Microbiological Letters 123, 343-347 (1994)). After homologous recombination by means of a cross-over event, the coding region of the gene in question is interrupted by the vector sequence, and two incomplete alleles are obtained, from each of which the 3'-end or the 5'-end is missing. This method was used, for example, by Fitzpatrick et al. (Applied Microbiology and Biotechnology 42, 575-580 (1994)) for the purpose of switching off the *recA* gene of *C. glutamicum*.

In the case of the method of gene replacement, a mutation such as, for example, a deletion, an insertion or a base-exchange in the gene of interest is produced in vitro. The allele that is produced is, in turn, cloned into a vector that is non-replicative in respect of *C. glutamicum* and

said vector is subsequently converted by transformation or conjugation into the desired host of *C. glutamicum*. After homologous recombination by means of a first cross-over event bringing about integration and by means of a suitable second cross-over event in the target gene or in the target sequence bringing about an excision, the incorporation of the mutation or of the allele is obtained. This method was used, for example, by Peters-Wendisch et al. (Microbiology 144, 915 - 927 (1998)), in order to switch off the *pyc* gene of *C. glutamicum* by a deletion.

In this way a deletion, an insertion or a base-exchange can be incorporated into the gene coding for 6-phosphofructokinase and/or the gene coding for 1-phosphofructokinase.

In addition, for the production of L-amino acids it can be advantageous, in addition to the attenuation of the gene coding for 6-phosphofructokinase and/or of the gene coding for 1-phosphofructokinase, to enhance, in particular to overexpress, one or more enzymes of the respective biosynthetic pathway, of glycolysis, of anaplerotic reactions, of the citric-acid cycle, of the pentose-phosphate cycle, of the export of amino acid and optionally regulatory proteins.

The term 'enhancement' or in this context describes the increase in the intracellular activity of one or more enzymes or proteins in a micro-organism which are coded by the corresponding DNA by, for example, the copy-number of the gene or genes being increased, by use being made of a strong promoter or a gene that codes for a corresponding enzyme or protein with a high activity and by optionally combining these measures.

By virtue of the measures of enhancement, in particular overexpression, the activity or concentration of the corresponding protein is increased in general by at least

10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, maximally up to 1000% or 2000%, relative to that of the wild-type protein or of the activity or concentration of the protein in the initial micro-organism.

- 5 The use of endogenous genes is generally preferred. The term "endogenous genes" or "endogenous nucleotide sequences" is to be understood to mean the genes or nucleotide sequences, respectively, existing in the population of a species.
- 10 Thus, for the preparation of L-lysine, in addition to the attenuation of the gene coding for 6-phosphofructokinase and/or of the gene coding for 1-phosphofructokinase, one or more of the genes selected from the group comprising
- the gene *lysC* coding for a feedback-resistant aspartate
15 kinase (Accession No. P26512, EP-B-0387527; EP-A-0699759; WO 00/63388),
 - the gene *dapA* coding for dihydrodipicolinate synthase (EP-B 0 197 335),
 - the gene *gap* coding for glyceraldehyde-3-phosphate
20 dehydrogenase (Eikmanns (1992), Journal of Bacteriology 174:6076-6086),
 - simultaneously the gene *pyc* coding for pyruvate carboxylase (DE-A-198 31 609),
 - the gene *mgo* coding for malate:quinone oxidoreductase
25 (Molenaar et al., European Journal of Biochemistry 254, 395 - 403 (1998)),
 - the gene *zwf* coding for glucose-6-phosphate dehydrogenase (JP-A-09224661),
 - simultaneously the gene *lysE* coding for the lysine-export
30 protein (DE-A-195 48 222),

- the gene *zwf1* coding for the *zwf1* protein (DE: 19959328.0, DSM 13115),
- the gene *tpi* coding for triosephosphate isomerase (Eikmanns (1992), Journal of Bacteriology 174:6076-6086),
5 and
- the gene *pgk* coding for 3-phosphoglycerate kinase (Eikmanns (1992), Journal of Bacteriology 174:6076-6086)

is/are enhanced, in particular overexpressed.

Moreover, for the production of amino acids, in particular
10 L-lysine, it can be advantageous, in addition to the attenuation of the gene coding for 6-phosphofructokinase and/or of the gene coding for 1-phosphofructokinase, simultaneously to attenuate, in particular to reduce the expression of, one or more of the genes selected from the
15 group comprising

- the gene *pck* coding for phosphoenolpyruvate carboxykinase (DE 199 50 409.1, DSM 13047),
- the gene *pgi* coding for glucose-6-phosphate isomerase (US 09/396,478, DSM 12969),
- 20 • the gene *poxB* coding for pyruvate oxidase (DE:1995 1975.7, DSM 13114),
- the gene *fda* coding for fructose bisphosphate aldolase (Mol. Microbiol. 3 (11), 1625-1637 (1989); gene bank Accession Number X17313) and
- 25 • the gene *zwa2* coding for the *zwa2* protein (DE: 19959327.2, DSM 13113).

Finally, for the production of amino acids it can be advantageous, in addition to the attenuation of the gene coding for 6-phosphofructokinase and/or of the gene coding

for 1-phosphofructokinase, to exclude undesirable side reactions (Nakayama: *Breeding of Amino Acid Producing Micro-organisms*, in: *Overproduction of Microbial Products*, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982).

The micro-organisms that are produced in accordance with the invention are likewise a subject of the invention and can be cultivated continuously or discontinuously in the batch process (batch cultivation) or in the fed-batch or repeated-fed-batch process for the purpose of producing L-amino acids. A summary of known cultivation methods is described in the textbook by Chmiel (*Bioprozesstechnik 1. Einführung in die Bioverfahrenstechnik* (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (*Bioreaktoren und periphere Einrichtungen* (Vieweg Verlag, Braunschweig/Wiesbaden, 1994)).

The culture medium to be used has to satisfy the demands of the respective strains in suitable manner. Descriptions of culture media of various micro-organisms are contained in the manual entitled *Manual of Methods for General Bacteriology* published by the American Society for Bacteriology (Washington D.C., USA, 1981).

Sugar and carbohydrates such as, for example, glucose, saccharose, lactose, fructose, maltose, molasses, starch and cellulose, oils and fats such as, for example, soybean oil, sunflower oil, peanut oil and coconut oil, fatty acids such as, for example, palmitic acid, stearic acid and linoleic acid, alcohols such as, for example, glycerin and ethanol, and organic acids such as, for example, acetic acid can be used by way of carbon source. These substances can be used individually or as a mixture.

Organic nitrogenous compounds such as peptones, yeast extract, meat extract, malt extract, maize steep liquor, soybean flour and urea, or inorganic compounds such as

ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate can be used by way of nitrogen source. The nitrogen sources can be used individually or as a mixture.

- 5 Phosphoric acid, potassium dihydrogenphosphate or dipotassium hydrogenphosphate or the corresponding sodium-containing salts can be used by way of phosphorus source. The culture medium must, moreover, contain salts of metals such as, for example, magnesium sulfate or iron sulfate,
10 that are necessary for growth. Finally, essential growth substances such as amino acids and vitamins can be employed in addition to the aforementioned substances. Besides, suitable precursors can be added to the culture medium. The stated feed materials can be added to the culture in
15 the form of a single charge or can be fed in during the cultivation in suitable manner.

- With a view to controlling the pH of the culture, basic compounds such as sodium hydroxide, potassium hydroxide, ammonia or ammoniacal liquor or acidic compounds such as
20 phosphoric acid or sulfuric acid are employed in suitable manner. With a view to controlling the formation of foam, anti-foaming agents such as, for example, fatty-acid polyglycol esters can be employed. With a view to maintaining the stability of plasmids, suitable substances
25 acting selectively, such as antibiotics for example, can be added to the medium. In order to maintain aerobic conditions, oxygen or oxygenous gas mixtures, such as air for example, are introduced into the culture. The temperature of the culture is normally around 20°C to 45°C
30 and preferably 25°C to 40°C. The culture is continued for such time until a maximum of the desired product has formed. This objective is normally attained within a period from 10 hours to 160 hours.

- Methods for the determination of L-amino acids are known
35 from the state of the art. The analysis can be undertaken

as described in Spackman et al. (Analytical Chemistry, 30, (1958), 1190) by anion-exchange chromatography with subsequent ninhydrin derivation, or it can be undertaken by reversed-phase HPLC, as described in Lindroth et al.

5 (Analytical Chemistry (1979) 51: 1167-1174).

The following micro-organism was deposited in the form of pure culture on 11 January 2002 in the Deutsche Sammlung für Mikroorganismen und Zellkulturen (German Collection of Micro-Organisms and Cell Cultures, DSMZ, Braunschweig, Germany):

10

- *Escherichia coli* DH5 α phamcr/pXK99EmobpfkB (= DH5 α mcr/pXK99EmobpfkB) as DSM 14741.

The present invention is elucidated in more detail in the following on the basis of exemplary embodiments.

Example 1

Preparation of a genomic cosmid gene bank from
Corynebacterium glutamicum ATCC 13032

- Chromosomal DNA from *Corynebacterium glutamicum* ATCC 13032
5 was isolated as described in Tauch et al. (1995, Plasmid
33:168-179) and partially cleaved with the restriction
enzyme Sau3AI (Amersham Pharmacia, Freiburg, Germany,
product description Sau3AI, Code No. 27-0913-02). The DNA
fragments were dephosphorylated with shrimp alkaline
10 phosphatase (Roche Diagnostics GmbH, Mannheim, Germany,
product description SAP, Code No. 1758250). The DNA of the
cosmid vector SuperCos1 (Wahl et al. (1987) Proceedings of
the National Academy of Sciences USA 84:2160-2164),
obtained from Stratagene (La Jolla, USA, product
15 description SuperCos1 Cosmid Vektor Kit, Code No. 251301)
was cleaved with the restriction enzyme XbaI (Amersham
Pharmacia, Freiburg, Germany, product description XbaI,
Code No. 27-0948-02) and likewise dephosphorylated with
shrimp alkaline phosphatase.
- 20 Subsequently the cosmid DNA was cleaved with the
restriction enzyme BamHI (Amersham Pharmacia, Freiburg,
Germany, product description BamHI, Code No. 27-0868-04).
The cosmid DNA that was treated in this way was mixed with
the treated ATCC13032 DNA, and the charge was treated with
25 T4-DNA-Ligase (Amersham Pharmacia, Freiburg, Germany,
product description T4-DNA-Ligase, Code No. 27-0870-04).
The ligation mixture was subsequently packaged in phages
with the aid of the Gigapack II XL Packing Extracts
(Stratagene, La Jolla, USA, product description Gigapack II
30 XL Packing Extract, Code No. 200217).

With a view to infection of the *E. coli* strain NM554
(Raleigh et al. 1988, Nucleic Acid Research 16:1563-1575),
the cells were taken up in 10 mM MgSO₄ and mixed with an
aliquot of the phage suspension. Infection and titration

of the cosmid bank were carried out as described in Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor), whereby the cells were plated onto LB agar (Lennox, 1955, Virology, 1:190) with 100 mg/l
5 ampicillin. After incubation overnight at 37°C, recombinant single clones were selected.

Example 2

Ascertainment of the upstream and downstream elongations of the sequences of the genes pfkA and pfkB known from the
10 state of the art

The cosmid DNA of a single colony was isolated with the Qiaprep Spin Miniprep Kit (Product No. 27106, Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions and partially cleaved with the restriction
15 enzyme Sau3AI (Amersham Pharmacia, Freiburg, Germany, product description Sau3AI, Product No. 27-0913-02). The DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany, product description SAP, Product No. 1758250). After gel-
20 electrophoretic fractionation, isolation of the cosmid fragments was effected within the size-range from 1500 to 2000 bp with the QiaExII Gel Extraction Kit (Product No. 20021, Qiagen, Hilden, Germany).

The DNA of the sequencing vector pZero-1 obtained from
25 Invitrogen (Groningen, Netherlands, product description Zero Background Cloning Kit, Product No. K2500-01) was cleaved with the restriction enzyme BamHI (Amersham Pharmacia, Freiburg, Germany, product description BamHI, Product No. 27-0868-04). The ligation of the cosmid
30 fragments into the sequencing vector pZero-1 was carried out as described by Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor), whereby the DNA mixture was incubated overnight with T4-Ligase (Pharmacia Biotech, Freiburg, Germany). This ligation

mixture was subsequently electroporated into the E. coli strain DH5 α MCR (Grant, 1990, Proceedings of the National Academy of Sciences U.S.A., 87:4645-4649) (Tauch et al. 1994, FEMS Microbiol Letters, 123:343-7) and plated onto LB agar (Lennox, 1955, Virology, 1:190) with 50 mg/l Zeocin.

The plasmid preparation of the recombinant clones was undertaken with a Biorobot 9600 (Product No. 900200, Qiagen, Hilden, Germany). Sequencing was effected in accordance with the dideoxy chain-termination method of Sanger et al. (1977, Proceedings of the National Academy of Sciences U.S.A., 74:5463-5467) with modifications in accordance with Zimmermann et al. (1990, Nucleic Acids Research, 18:1067). Use was made of the "RR dRhodamin Terminator Cycle Sequencing Kit" manufactured by PE Applied Biosystems (Product No. 403044, Weiterstadt, Germany). Gel-electrophoretic fractionation and analysis of the sequencing reaction were undertaken in a "Rotiphorese NF Acrylamid/Bisacrylamid" gel (29:1) (Product No. A124.1, Roth, Karlsruhe, Germany) with an "ABI Prism 377" sequencer manufactured by PE Applied Biosystems (Weiterstadt, Germany).

The raw sequence data obtained were subsequently processed by applying the Staden program package (1986, Nucleic Acids Research, 14:217-231) Version 97-0. The individual sequences of the pZero1 derivatives were assembled into a coherent contig. The computer-aided coding-region analysis was produced with the program XNIP (Staden, 1986, Nucleic Acids Research, 14:217-231).

The known nucleotide sequences of the genes pfkA and pfkB that are extended by the upstream and downstream elongations obtained in this way are represented in SEQ ID No. 1 and SEQ ID No. 3.

Example 3

Preparation of the expression vector pXK99Emobpfb for IPTG-induced expression of the pfb gene in *C. glutamicum*

3.1 Cloning of the pfb gene

- 5 Chromosomal DNA is isolated from the strain ATCC 13032 in accordance with the method of Eikmanns et al. (Microbiology 140: 1817-1828 (1994)). On the basis of the known sequence of the pfb gene for *C. glutamicum* the following oligonucleotides for the polymerase chain reaction are
10 selected (see SEQ ID No. 5 and SEQ ID No. 6):

pfb for:

5'-CT TCT AGA-CCC GAC CAC AAC TTT CAG G -3'

pfbint int:

5'- AG AAG CTT-GCC AGG TGT ATC CAA GCT CTC -3'

- 15 In this connection the primers are selected in such a way that the amplified fragment contains the incomplete gene, beginning with the native ribosome binding site without promoter region, as well as the anterior region of the pfb gene. In addition, the primer pfb for contains the
20 sequence for the cleavage site of the restriction endonuclease XbaI, and the primer pfb int contains the sequence for the cleavage site of the restriction endonuclease HindIII, which are marked by underlining in the nucleotide sequences represented above.
- 25 The primers that are represented are synthesised by MWG-Biotech AG (Ebersberg, Germany), and the PCR reaction is carried out in accordance with the standard PCR method of Innis et al. (PCR Protocols. A Guide to Methods and Applications, 1990, Academic Press) with Pwo polymerase
30 produced by Roche Diagnostics GmbH (Mannheim, Germany). With the aid of the polymerase chain reaction the primers enable the amplification of a 594-bp DNA fragment that

bears the incomplete *pfkB* gene including the native ribosome binding site.

The 594-bp *pfkB* fragment is cleaved with the restriction endonucleases *Xba*I and *Hind*III and is subsequently isolated
5 from the agarose gel with the QiaExII Gel Extraction Kit (Product No. 20021, Qiagen, Hilden, Germany).

3.2 Construction of the expression vector pXK99Emob

The IPTG-inducible expression vector pXK99Emob is constructed in accordance with the state of the art. The
10 vector is based on the *Escherichia coli* expression vector pTRC99A (Amann et al., Gene 69: 301-315 (1988)) and contains the *trc* promoter which is inducible by addition of the lactose derivative IPTG (isopropyl- β -D-thiogalactopyranoside), the termination regions T1 and T2,
15 the replication origin *ColE1* from *E. coli*, the *lacI^q* gene (repressor of the *lac* operon of *E. coli*), a multiple cloning site (*mcs*) (Norrander, J.M. et al. Gene 26, 101-106 (1983)), the kanamycin-resistance gene *aph(3')*-IIa from *E. coli* (Beck et al. (1982), Gene 19: 327-336) and the RP4
20 mobilization site from the cloning vector pK18mobsacB (Schäfer et al., Gene 14: 69-73 (1994)).

It has been found that the vector pXK99Emob is quite especially suitable for regulating the expression of a gene, in particular for bringing about the attenuated
25 expression in coryneform bacteria. The vector pXK99Emob is an *E. coli* expression vector and can be employed in *E. coli* for the enhanced expression of a gene.

Since the vector cannot replicate independently in coryneform bacteria, it is preserved in the cell only when
30 it integrates into the chromosome. The peculiarity of this vector in this connection is the use for the regulated expression of a gene after cloning of a gene segment from the anterior region of the corresponding gene into the

vector, containing the start codon and the native ribosome binding site, and after subsequent integration of the vector in coryneform bacteria, in particular *C. glutamicum*. By addition of metered amounts of IPTG to the nutrient medium the gene expression is regulated. In this connection, quantities from 0.5 μM up to 10 μM IPTG bring about a very weak expression of the corresponding gene, and quantities from 10 μM up to 100 μM bring about a slightly attenuated to normal expression of the corresponding gene.

- 10 The constructed *E. coli* expression vector pXK99Emob is transferred by means of electroporation (Tauch et al. 1994, FEMS Microbiol Letters, 123: 343-347) into *E. coli* DH5 α mcr (Grant, 1990, Proceedings of the National Academy of Sciences U.S.A., 87:4645-4649). Selection of the transformants is undertaken on LB agar (Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989) that has been supplemented with 50 mg/l kanamycin.

- 20 Plasmid DNA is isolated from a transformant in accordance with the customary methods (Peters-Wendisch et al., 1998, Microbiology, 144, 915 - 927), is cut with the restriction endonuclease NcoI, and the plasmid is examined by subsequent agarose-gel electrophoresis.

- 25 The plasmid construct that is obtained in this way is designated as pXK99Emob (Figure 1). The strain that is obtained by electroporation of the plasmid pXK99Emob into the *E. coli* strain DH5 α mcr is called *E. coli* DH5 α mcr/pXK99Emob.

- 3.3 Cloning of the pfkB fragment into the *E. coli* expression vector pXK99Emob

By way of vector, use is made of the *E. coli* expression vector pXK99Emob described in Example 3.2. DNA of this plasmid is cleaved completely with the restriction enzymes

XbaI and HindIII and is subsequently dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany, product description SAP, Product No. 1758250).

- 5 The approximately 580-bp pfkB fragment described in Example 3.1, which is obtained by means of PCR and cleaved with the restriction endonucleases XbaI and HindIII, is mixed with the prepared vector pXK99Emob, and the charge is treated with T4-DNA-Ligase (Amersham Pharmacia, Freiburg, Germany, product description T4-DNA-Ligase, Code No. 27-0870-04).
10 The ligation charge is transformed into the E. coli strain DH5 α mc (Hanahan, In: DNA Cloning. A Practical Approach, Vol. I, IRL Press, Oxford, Washington DC, USA). Selection of plasmid-bearing cells is undertaken by plating the transformation charge onto LB agar (Lennox, 1955, Virology, 1:190) with 50 mg/l kanamycin. After incubation overnight at 37°C, recombinant individual clones are selected. Plasmid DNA is isolated from a transformant with the Qiaprep Spin Miniprep Kit (Product No. 27106, Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions and is cleaved with the restriction enzymes XbaI and HindIII, in order to examine the plasmid by subsequent agarose-gel electrophoresis. The plasmid that is obtained is called pXK99EmobpfkB. It is represented in
25 Figure 2.

Example 4

Integration of the vector pXK99EmobpfkB into the genome of the C. glutamicum strain DSM5715

- The vector pXK99EmobpfkB named in Example 3 is
30 electroporated into the strain C. glutamicum DSM5715 in accordance with the electroporation method of Tauch et al. (1989 FEMS Microbiology Letters 123: 343-347). The vector cannot replicate independently in DSM5715 and is preserved in the cell only when it has integrated into the

chromosome. Selection of clones with integrated
~~pXK99EmobpfbB~~ is undertaken by plating the electroporation
charge onto LB agar (Sambrook et al., Molecular Cloning: A
Laboratory Manual, 2nd Ed., Cold Spring Harbor, New York,
5 1989) that has been supplemented with 15 mg/l kanamycin and
IPTG (1 mM).

A selected kanamycin-resistant clone that has inserted the
plasmid pXK99EmobpfbB named in Example 3 within the
chromosomal pfbB gene of DSM5715 is designated as
10 DSM5715::pXK99EmobpfbB.

Example 5

Preparation of lysine

The *C. glutamicum* strain DSM5715::pCXK99EmobpfbB obtained
in Example 4 is cultured in a nutrient medium that is
15 suitable for the production of lysine, and the lysine
content in the supernatant of the culture is determined.
Addition of IPTG results in an attenuated expression of the
pfbB gene, regulated by the trc promoter.

To this end, the strain is firstly incubated for 24 hours
20 at 33°C on agar plate with the appropriate antibiotic
(brain/heart agar with kanamycin (25 mg/l) and IPTG
(10 µM)). Starting from this agar-plate culture, a
preculture is inoculated (10 ml medium in a 100-ml
Erlenmeyer flask). The complete medium Cg III is used as
25 medium for the preculture.

Medium Cg III

NaCl 2.5 g/l
bacto-peptone 10 g/l
bacto-yeast extract 10 g/l
glucose (autoclaved separately) 2% (w/v)

The pH value was adjusted to pH
7.4

To this medium there are added kanamycin (25 mg/l) and IPTG (10 μ M). The preculture is incubated on the shaker for 16 hours at 33°C at 240 rpm. A main culture is inoculated
5 from this preculture, so that the initial OD (660 nm) of the main culture amounts to 0.1. The medium MM is used for the main culture.

To this medium there were added kanamycin (25 mg/l) and IPTG (10 μ M). The preculture was incubated on the shaker
10 for 16 hours at 33°C at 240 rpm. The OD (660) of the preculture amounted to 14.7. 68 μ l from this preculture were inoculated into a main culture, so that the initial OD (660 nm) of the main culture amounted to 0.1. By virtue of the transfer of IPTG-containing medium from the preculture,
15 the IPTG concentration in the main culture amounted to about 0.07 μ M/l. The medium MM was used for the main culture.

Medium MM

CSL (corn steep liquor)	5 g/l
MOPS (morpholinopropanesulfonic acid)	20 g/l
glucose (autoclaved separately)	50 g/l
salts:	
(NH ₄) ₂ SO ₄	25 g/l
KH ₂ PO ₄	0.1 g/l
MgSO ₄ * 7 H ₂ O	1.0 g/l
CaCl ₂ * 2 H ₂ O	10 mg/l
FeSO ₄ * 7 H ₂ O	10 mg/l
MnSO ₄ * H ₂ O	5.0 mg/l
biotin (sterilized by filtration)	0.3 mg/l
thiamin * HCl (sterilized by filtration)	0.2 mg/l
leucine (sterilized by filtration)	0.1 g/l
CaCO ₃	25 g/l

CSL, MOPS and the salt solution are adjusted to pH 7 with ammoniacal liquor and are autoclaved. Subsequently the sterile substrate and vitamin solutions are added, as well
5 as the dry-autoclaved CaCO₃.

Culturing is effected in 10 ml volumes in a 100-ml Erlenmeyer flask with baffles. Kanamycin (25 mg/l) is added. Culturing is effected at 33°C and at 80% atmospheric moisture.

After 48 hours the OD at a measuring wavelength of 660 nm is ascertained with a Biomek 1000 (Beckmann Instruments GmbH, Munich). The quantity of lysine that is formed is determined with an amino-acid analyzer manufactured by
5 Eppendorf-BioTronik (Hamburg, Germany) by ion-exchange chromatography and post-column derivation with detection of ninhydrin.

The result of the experiment is represented in Table 1.

Table 1

Strain	OD (660 nm)	Lysine HCl g/l
DSM5715	12.2	15.31
DSM5715::pXK99EmobpfkB	7.8	16.89

10

Brief description of the Figures:

Figure 1: map of the plasmid pXK99Emob,

Figure 2: map of the plasmid pXK99EmobpfkB.

The abbreviations and designations that are used have the
15 following significance.

Kan:	kanamycin-resistance gene aph(3')-IIa from Escherichia coli
HindIII	cleavage site of the restriction enzyme HindIII
NcoI	cleavage site of the restriction enzyme NcoI
XbaI	cleavage site of the restriction enzyme XbaI
RP4-mob	RP4 mobilization site
P _{trc}	trc promoter
T1	termination region T1
T2	termination region T2
lacI _q	lacI _q repressor of the lac operon of Escherichia coli
ori _V	replication origin ColE1 from E. coli
pfkB	cloned region of the pfkB gene

What is claimed is:

1. A polynucleotide isolated from coryneform bacteria,
containing elongated polynucleotide sequences coding
for 1-phosphofructokinase and/or 6-
phosphofructokinase, wherein said sequences are each
elongated in front of the start codon and behind the
stop codon of the gene, in each instance by up to
about 700 base-pairs.
2. Isolated polynucleotide according to Claim 1,
containing (a) polynucleotide sequence(s) coding for
1-phosphofructokinase and/or 6-phosphofructokinase,
wherein said sequence(s) are elongated in front of the
start codon and behind the stop codon of the gene, in
each instance by up to about 700 base-pairs, the
elongated amino-acid sequences being represented in
SEQ ID No. 3 for the 1-phosphofructokinase gene and in
SEQ ID No. 1 for the 6-phosphofructokinase gene and
the elongations in comparison with the sequences known
from the state of the art consisting in SEQ ID No. 3
of base-pairs 1 to 508 and 1684 to 2234 and in
SEQ ID No. 1 of base-pairs 1 to 531 and 1621 to 2160.
3. A process for the fermentative preparation of L-amino
acids, in particular L-lysine, wherein the following
steps are implemented:
 - a) fermentation of the coryneform bacteria producing
the desired L-amino acid, in which at least the
gene coding for 6-phosphofructokinase and/or the
gene coding for 1-phosphofructokinase are/is
attenuated,
 - b) enrichment of the desired product in the medium
or in the cells of the bacteria, and
 - c) isolation of the desired L-amino acid, whereby
constituents of the fermentation broth and/or of

the biomass optionally remain in the end product in proportions or in their total quantities.

4. Process according to Claim 3, wherein coryneform bacteria are employed in which the attenuation is achieved by using the polynucleotide sequences that are elongated in front of the start codon and behind the stop codon of the respective gene by, in each instance, 300 to 800 base-pairs.
5. Process according to Claim 4, wherein coryneform bacteria are employed in which the attenuation is achieved by using the polynucleotide sequences that are elongated in front of the start codon and behind the stop codon of the gene, in each instance by about 700 base-pairs, the elongated nucleotide sequences being represented in SEQ ID No. 3 for the 1-phosphofructokinase gene and in SEQ ID No. 1 for the 6-phosphofructokinase gene and the elongations in SEQ ID No. 3 in comparison with the sequence known from the state of the art consisting of base-pairs 1 to 508 and 1684 to 2234 and in SEQ ID No. 1 in comparison with the sequence known from the state of the art consisting of base-pairs 1 to 531 and 1621 to 2160.
6. Process according to Claim 3, wherein bacteria are employed in which, in addition, further genes of the biosynthetic pathway of the desired L-amino acid are enhanced.
7. Process according to Claim 3, wherein bacteria are employed in which the metabolic pathways that diminish the formation of the desired L-amino acid are at least partially switched off.
8. Process according to Claim 3, wherein the expression of the polynucleotide(s) that codes/code for 6-

phosphofructokinase and/or for 1-phosphofructokinase is diminished.

9. Process according to Claim 3, wherein the catalytic properties of the polypeptide(s) (enzyme protein(s))
5 for which the polynucleotide(s) from SEQ ID NO. 1 and SEQ ID No. 3 codes/code are reduced.
10. Process according to Claim 3, wherein for the preparation of L-lysine coryneform micro-organisms are fermented in which simultaneously one or more of the
10 genes selected from the group comprising
- 10.1 the gene lysC coding for a feedback-resistant aspartate kinase,
 - 10.2 the gene dapA coding for dihydrodipicolinate synthase,
 - 15 10.3 the gene gap coding for glyceraldehyde-3-phosphate dehydrogenase,
 - 10.4 the gene pyc coding for pyruvate carboxylase,
 - 10.5 the gene mqo coding for malate:quinone
20 oxidoreductase,
 - 10.6 the gene zwf coding for glucose-6-phosphate dehydrogenase,
 - 10.7 simultaneously the gene lysE coding for lysine export,
 - 25 10.8 the gene zwal coding for the zwal protein,
 - 10.9 the gene tpi coding for triosephosphate isomerase, and
 - 10.10 the gene pgk coding for 3-phosphoglycerate kinase

is/are enhanced, in particular overexpressed.

11. Process according to Claim 3, wherein with a view to preparing L-amino acids coryneform micro-organisms are fermented in which simultaneously one or more of the genes selected from the group comprising
- 5 11.1 the pck gene coding for phosphoenolpyruvate carboxykinase,
- 11.2 the pgi gene coding for glucose-6-phosphate isomerase,
- 10 11.3 the gene poxB coding for pyruvate oxidase,
- 11.4 the gene fda coding for fructose bisphosphate aldolase, and
- 11.5 the gene zwa2 coding for the zwa2 protein
- is/are attenuated.
- 15 12. Process according to one or more of Claims 3 to 11, wherein micro-organisms of the species *Corynebacterium glutamicum* are employed.
13. Coryneform bacteria in which at least the gene coding for 6-phosphofructokinase and/or the gene coding for
- 20 1-phosphofructokinase are/is present in attenuated form.
14. *Escherichia coli* strain DH5 α hamcr/pXK99Emobpfb (= DH5 α mcr/ pXK99Emobpfb), deposited as DSM 14741 in the Deutschen Sammlung für Mikroorganismen und
- 25 Zellkulturen (German Collection of Micro-Organisms and Cell Cultures), Braunschweig, Germany.

Figure 1: Plasmid pXK99Emob





Figure 2: pXK99EmobpfkB



SEQUENCE LISTING

5 <110> Degussa AG
 <120> Process for the preparation of
 L-amino acids by using coryneform bacteria
 10 <130> 010103
 <160> 6
 <170> PatentIn version 3.1
 15 <210> 1
 <211> 2234
 <212> DNA
 <213> Corynebacterium glutamicum
 20 <220>
 <221> CDS
 <222> (632)..(1660)
 <223> pfkA-Gen
 25 <400> 1
 cctctaataa gagtcgcccc gataagtttt ttaccgtaa ttattactgg gagtcagata 60
 ctgcgtaagc aatcgacgca gcgccagcgg tcacagtaag aactgcaggc cacgcgcaa 120
 30 tcttcttggc aagtgggtgg gacaggccaa atgcaccaac gtaggttgcc agcaggccag 180
 tagctactgc aggacccttc ttttcattcc agcttcgtgc agcaagcgt cccgatgctg 240
 ccaatggaat ggtgcccagt gggcgaatgc cggattcacg ggcagtcaac caaccgccga 300
 35 tcaaacctgc tgcgacgacg gtggcagtgc tgacctggga tgcctttttc aatttcattt 360
 ccatggtgag ccagtctaga gacaaaattt ttccgcgggg gttttcttga tctgatccga 420
 40 caacccaatg ggggcaaaaa tgtgtccgac caaaaattgt gcagcacacc acatgcccgc 480
 tcggacaatg tcgatttggt aatgaaactg cagctctggc gattaaataa gatggtcaga 540
 gacagttttt tggcctgtca acccctgtga ttctcttatt tttgggtgat tgttccggcg 600
 45 cgggtgttgt gatgggttta atatggaaga c atg cga att gct act ctc acg 652
 Met Arg Ile Ala Thr Leu Thr
 1 5
 50 tca ggc ggc gac tgc ccc gga cta aac gcc gtc atc cga gga atc gtc 700
 Ser Gly Gly Asp Cys Pro Gly Leu Asn Ala Val Ile Arg Gly Ile Val
 10 15 20
 55 cgc aca gcc agc aat gaa ttt ggc tcc acc gtc gtt ggt tat caa gac 748
 Arg Thr Ala Ser Asn Glu Phe Gly Ser Thr Val Val Gly Tyr Gln Asp
 25 30 35
 ggt tgg gaa gga ctg tta ggc gat cgt cgc gta cag ctg tat gac gat 796
 Gly Trp Glu Gly Leu Leu Gly Asp Arg Arg Val Gln Leu Tyr Asp Asp
 40 45 50 55

	gaa	gat	att	gac	cga	atc	ctc	ctt	cga	ggc	ggc	acc	att	ttg	ggc	act	844
	Glu	Asp	Ile	Asp	Arg	Ile	Leu	Leu	Arg	Gly	Gly	Thr	Ile	Leu	Gly	Thr	
				60					65					70			
5	ggt	cgc	ctc	cat	cgc	gac	aag	ttt	aag	gcc	gga	att	gat	cag	att	aag	892
	Gly	Arg	Leu	His	Pro	Asp	Lys	Phe	Lys	Ala	Gly	Ile	Asp	Gln	Ile	Lys	
				75					80					85			
10	gcc	aac	tta	gaa	gac	gcc	ggc	atc	gat	gcc	ctt	atc	cca	atc	ggg	ggc	940
	Ala	Asn	Leu	Glu	Asp	Ala	Gly	Ile	Asp	Ala	Leu	Ile	Pro	Ile	Gly	Gly	
			90					95					100				
15	gaa	gga	acc	ctg	aag	ggg	gcc	aag	tgg	ctg	tct	gat	aac	ggg	atc	cct	988
	Glu	Gly	Thr	Leu	Lys	Gly	Ala	Lys	Trp	Leu	Ser	Asp	Asn	Gly	Ile	Pro	
		105					110					115					
20	gtt	gtc	ggg	gtc	cca	aag	acc	att	gac	aat	gac	gtg	aat	ggc	act	gac	1036
	Val	Val	Gly	Val	Pro	Lys	Thr	Ile	Asp	Asn	Asp	Val	Asn	Gly	Thr	Asp	
		120				125					130					135	
25	ttc	acc	ttc	ggg	ttc	gat	act	gct	gtg	gca	gtg	gct	acc	gac	gct	gtt	1084
	Phe	Thr	Phe	Gly	Phe	Asp	Thr	Ala	Val	Ala	Val	Ala	Thr	Asp	Ala	Val	
					140					145					150		
30	gac	cgc	ctg	cac	acc	acc	gct	gaa	tct	cac	aac	cgt	gtg	atg	atc	gtg	1132
	Asp	Arg	Leu	His	Thr	Thr	Ala	Glu	Ser	His	Asn	Arg	Val	Met	Ile	Val	
				155					160					165			
35	gag	gtc	atg	ggc	cgc	cac	gtg	ggg	tgg	att	gct	ctg	cac	gca	ggg	atg	1180
	Glu	Val	Met	Gly	Arg	His	Val	Gly	Trp	Ile	Ala	Leu	His	Ala	Gly	Met	
			170					175					180				
40	gcc	ggc	ggg	gct	cac	tac	acc	gtt	att	cca	gaa	gta	cct	ttc	gat	att	1228
	Ala	Gly	Gly	Ala	His	Tyr	Thr	Val	Ile	Pro	Glu	Val	Pro	Phe	Asp	Ile	
		185					190					195					
45	gca	gag	atc	tgc	aag	gcg	atg	gaa	cgt	cgc	ttc	cag	atg	ggc	gag	aag	1276
	Ala	Glu	Ile	Cys	Lys	Ala	Met	Glu	Arg	Arg	Phe	Gln	Met	Gly	Glu	Lys	
		200				205					210					215	
50	tac	ggc	att	atc	gtc	gtt	gcg	gaa	ggg	gcg	ttg	cca	cgc	gaa	ggc	acc	1324
	Tyr	Gly	Ile	Ile	Val	Val	Ala	Glu	Gly	Ala	Leu	Pro	Arg	Glu	Gly	Thr	
					220					225					230		
55	atg	gag	ctt	cgt	gaa	ggc	cac	att	gac	cag	ttc	ggg	cac	aag	acc	ttc	1372
	Met	Glu	Leu	Arg	Glu	Gly	His	Ile	Asp	Gln	Phe	Gly	His	Lys	Thr	Phe	
				235					240					245			
60	acg	gga	att	gga	cag	cag	atc	gct	gat	gag	atc	cac	gtg	cgc	ctc	ggc	1420</

gct cgt gcg tgc cat gag gga agc ttt gac aag gtt gtt gct ttg aag 1564
 Ala Arg Ala Cys His Glu Gly Ser Phe Asp Lys Val Val Ala Leu Lys
 300 305 310

5 ggt gag agc att gag atg atc acc ttt gaa gaa gca gtc gga acc ttg 1612
 Gly Glu Ser Ile Glu Met Ile Thr Phe Glu Glu Ala Val Gly Thr Leu
 315 320 325

10 aag gaa gtt cca ttc gaa cgc tgg gtt act gcc cag gca atg ttt gga 1660
 Lys Glu Val Pro Phe Glu Arg Trp Val Thr Ala Gln Ala Met Phe Gly
 330 335 340

tagtttttcg ggcttttatc aacagccaat aacagctctt tcgcccattg aggtggaggg 1720

15 gctgtttttt catgccgtaa ggaaagtgca agtaagtga atcaagtggc ctagatccat 1780

tgacacttag actgtgacct aggcttgact ttcgtggggg agtggggata agttcatctt 1840

20 aaacacaatg caatcgattg catttacgtt ccttatccca caataggggt acctccaga 1900

aagttggtga ggagatggct tccgaaacct ccagcccgaa gaagcgggcc accacgtca 1960

aagacatcgc gcaagcaaca cagctttcag tcagcacggt gtcccgggca ttggccaaca 2020

25 acgcgagcat tccggaatcc acacgcatcc gagtggttga agccgctcaa aagctgaact 2080

accgtcccaa tgcccaagct cgtgcattgc ggaagtcgag gacagacacc atcgggtgca 2140

30 tcattccaaa cattgagaac ccatatttct cctcactagc agcatcgatt caaaaagctg 2200

ctcgtgaagc tggggtgtcc accattttgt ccaa 2234

<210> 2
 <211> 343
 35 <212> PRT
 <213> *Corynebacterium glutamicum*

<400> 2
 40 Met Arg Ile Ala Thr Leu Thr Ser Gly Gly Asp Cys Pro Gly Leu Asn
 1 5 10 15

Ala Val Ile Arg Gly Ile Val Arg Thr Ala Ser Asn Glu Phe Gly Ser
 20 25 30

45 Thr Val Val Gly Tyr Gln Asp Gly Trp Glu Gly Leu Leu Gly Asp Arg
 35 40 45

Arg Val Gln Leu Tyr Asp Asp Glu Asp Ile Asp Arg Ile Leu Leu Arg
 50 55 60

Gly Gly Thr Ile Leu Gly Thr Gly Arg Leu His Pro Asp Lys Phe Lys
 65 70 75 80

55 Ala Gly Ile Asp Gln Ile Lys Ala Asn Leu Glu Asp Ala Gly Ile Asp
 85 90 95

Ala Leu Ile Pro Ile Gly Gly Glu Gly Thr Leu Lys Gly Ala Lys Trp
 100 105 110

60 Leu Ser Asp Asn Gly Ile Pro Val Val Gly Val Pro Lys Thr Ile Asp
 115 120 125

	Asn	Asp	Val	Asn	Gly	Thr	Asp	Phe	Thr	Phe	Gly	Phe	Asp	Thr	Ala	Val
	130						135					140				
5	Ala	Val	Ala	Thr	Asp	Ala	Val	Asp	Arg	Leu	His	Thr	Thr	Ala	Glu	Ser
	145					150					155					160
	His	Asn	Arg	Val	Met	Ile	Val	Glu	Val	Met	Gly	Arg	His	Val	Gly	Trp
					165						170				175	
10	Ile	Ala	Leu	His	Ala	Gly	Met	Ala	Gly	Gly	Ala	His	Tyr	Thr	Val	Ile
				180					185					190		
	Pro	Glu	Val	Pro	Phe	Asp	Ile	Ala	Glu	Ile	Cys	Lys	Ala	Met	Glu	Arg
			195					200					205			
15	Arg	Phe	Gln	Met	Gly	Glu	Lys	Tyr	Gly	Ile	Ile	Val	Val	Ala	Glu	Gly
	210						215					220				
20	Ala	Leu	Pro	Arg	Glu	Gly	Thr	Met	Glu	Leu	Arg	Glu	Gly	His	Ile	Asp
	225					230					235					240
	Gln	Phe	Gly	His	Lys	Thr	Phe	Thr	Gly	Ile	Gly	Gln	Gln	Ile	Ala	Asp
					245					250					255	
25	Glu	Ile	His	Val	Arg	Leu	Gly	His	Asp	Val	Arg	Thr	Thr	Val	Leu	Gly
				260					265					270		
	His	Ile	Gln	Arg	Gly	Gly	Thr	Pro	Thr	Ala	Phe	Asp	Arg	Val	Leu	Ala
			275					280					285			
30	Thr	Arg	Tyr	Gly	Val	Arg	Ala	Ala	Arg	Ala	Cys	His	Glu	Gly	Ser	Phe
	290						295					300				
35	Asp	Lys	Val	Val	Ala	Leu	Lys	Gly	Glu	Ser	Ile	Glu	Met	Ile	Thr	Phe
	305					310					315					320
	Glu	Glu	Ala	Val	Gly	Thr	Leu	Lys	Glu	Val	Pro	Phe	Glu	Arg	Trp	Val
					325					330					335	
40	Thr	Ala	Gln	Ala	Met	Phe	Gly									
				340												
45	<210>	3														
	<211>	2160														
	<212>	DNA														
	<213>	Corynebacterium glutamicum														
50	<220>															
	<221>	CDS														
	<222>	(609)..(1598)														
	<223>	pfkB-Gen														
55	<400>	3														
	cccatgggta	cgtctccccc	tcggctgaaa	cctgccttgg	ttaaaggaat	gccaccggaa										60
	ccccgtgttt	tagaacttgc	agaaactgca	gtttccctca	tcacacctct	agcacgcagc										120
60	attttcctgg	attcaggttt	agcgtgcacg	gcgattgcca	cgggtgttggg	ggatcctcca										180
	gaagatgcca	ggtggactgt	tgttacaagt	tcccccggcg	ctgtgattgc	cttgtccgcg										240

	acagatgcc	acacacggt	ggtgctgcac	gggcaggttc	acggttaattg	ttcttcaatc	300
5	attgggtcca	cggcagtaga	catgatttcg	cagttgcgcg	ctgatatcgc	cttcgtggag	360
	gttgatgcga	ttcaatccga	tacaagtctg	tgacagtttt	tcccggagac	gattcccatc	420
	aagcaagcca	tgatcaaaaa	cgcggttttc	acagttgctg	ttctcagccc	gagatctccc	480
10	caagatcaag	aacttcaact	tttgaagcac	cctttttcca	ccttggtgga	ttttgatgcc	540
	cttggtaccg	atgaccacac	gctagatttt	ccagttttgc	ccgaccacaa	ctttcagggtg	600
15	gtaacccc	atg atc atc	aca ttc acc	cca aac ccg	agt att gat	tcc acg	650
		Met Ile Ile	Thr Phe Thr	Pro Asn Pro	Ser Ile Asp	Ser Thr	
	1		5		10		
	ctg tgc ctc	ggc gaa gag	ctc tcc cgt	gga tcc gtc	caa cga ctt	gat	698
20	Leu Ser Leu	Gly Glu Glu	Leu Ser Arg	Gly Ser Val	Gln Arg Leu	Asp	
	15	20		25	30		
	tcc gtc acc	gct gtc gca	ggt ggt aaa	ggc atc aat	gtc gcc cac	gct	746
	Ser Val Thr	Ala Val Ala	Gly Gly Lys	Gly Ile Asn	Val Ala His	Ala	
25		35	40	45			
	gtc ttg ctt	gcg ggc ttt	gaa acc ttg	gct gtg ttc	cca gcc ggc	aag	794
	Val Leu Leu	Ala Gly Phe	Glu Thr Leu	Ala Val Phe	Pro Ala Gly	Lys	
		50	55	60			
30	ctc gac ccc	ttc gtc cca	ctg gtc cgc	gac atc ggc	ttg ccc gtg	gaa	842
	Leu Asp Pro	Phe Val Pro	Leu Val Arg	Asp Ile Gly	Leu Pro Val	Glu	
	65	70	75				
35	act gtt gtg	atc aac aag	aac gtc cgc	acc aac acc	aca gtc acc	gaa	890
	Thr Val Val	Ile Asn Lys	Asn Val Arg	Thr Asn Thr	Val Thr Thr	Glu	
	80	85	90				
	ccg gac ggc	acc acc acc	aag ctc aac	ggc ccc ggc	gcg ccg ctc	agc	938
40	Pro Asp Gly	Thr Thr Thr	Lys Leu Asn	Gly Pro Gly	Ala Pro Leu	Ser	
	95	100	105	110			
	gag cag aag	ctc cgt agc	ttg gaa aag	gtg ctt atc	gac gcg ctc	cgc	986
	Glu Gln Lys	Leu Arg Ser	Leu Glu Lys	Val Leu Ile	Asp Ala Leu	Arg	
45		115	120	125			
	ccc gaa gtc	acc tgg gtt	gtc ctg gcg	ggc tgc ctg	cca cca ggg	gca	1034
	Pro Glu Val	Thr Trp Val	Val Val Leu	Ala Gly Ser	Leu Pro Pro	Gly Ala	
		130	135	140			
50	cca gtt gac	tgg tac gcg	cgt ctc acc	gcg ttg atc	cat tca gca	cgc	1082
	Pro Val Asp	Trp Tyr Ala	Arg Leu Thr	Ala Leu Ile	His Ser Ala	Arg	
	145	150	155				
55	cct gac gtt	cgc gtg gct	gtc gat acc	tca gac aag	cca ctg atg	gcg	1130
	Pro Asp Val	Arg Val Ala	Val Asp Thr	Ser Asp Lys	Pro Leu Met	Ala	
	160	165	170				
60	ttg ggc gag	agc ttg gat	aca cct ggc	gct gct ccg	aac ctg att	aag	1178
	Leu Gly Glu	Ser Leu Asp	Thr Pro Gly	Ala Ala Pro	Asn Leu Ile	Lys	
	175	180	185	190			

	cca aat ggt ctg gaa ctg ggc cag ctg gct aac act gat ggt gaa gag	1226
	Pro Asn Gly Leu Glu Leu Gly Gln Leu Ala Asn Thr Asp Gly Glu Glu	
	195 200 205	
5	ctg gag gcg cgt gct gcg caa ggc gat tac gac gcc atc atc gca gct	1274
	Leu Glu Ala Arg Ala Ala Gln Gly Asp Tyr Asp Ala Ile Ile Ala Ala	
	210 215 220	
10	gcg gac gta ctg gtt aac cgt ggc atc gaa cag gtg ctt gtc acc ttg	1322
	Ala Asp Val Leu Val Asn Arg Gly Ile Glu Gln Val Leu Val Thr Leu	
	225 230 235	
15	ggt gcc gca gga gcg gtg ttg gtc aac gca gaa ggt gcg tgg act gct	1370
	Gly Ala Ala Gly Ala Val Leu Val Asn Ala Glu Gly Ala Trp Thr Ala	
	240 245 250	
20	act tct cca aag att gat gtt gta tcc acc gtt gga gct gga gac tgt	1418
	Thr Ser Pro Lys Ile Asp Val Val Ser Thr Val Gly Ala Gly Asp Cys	
	255 260 265 270	
25	gct ctt gca ggt ttt gtt atg gca cgt tcc cag aag aaa aca ctg gag	1466
	Ala Leu Ala Gly Phe Val Met Ala Arg Ser Gln Lys Lys Thr Leu Glu	
	275 280 285	
30	gaa tct ctg ctg aat gcc gtg tct tac ggc tgc act gcg gcg tct ctt	1514
	Glu Ser Leu Leu Asn Ala Val Ser Tyr Gly Ser Thr Ala Ala Ser Leu	
	290 295 300	
35	cct ggc act acc att cct cgt cct gac caa ctc gcc aca gct ggt gca	1562
	Pro Gly Thr Thr Ile Pro Arg Pro Asp Gln Leu Ala Thr Ala Gly Ala	
	305 310 315	
40	acg gtc acc caa gtc aaa gga ttg aaa gaa tca gca tgaatagcgt	1608
	Thr Val Thr Gln Val Lys Gly Leu Lys Glu Ser Ala	
	320 325 330	
45	aaataattcc tcgcttgctc ggctggatgt cgatttcggc gactccacca cggatgtcat	1668
	caacaacctt gccactgtta ttttcgacgc tggccgagct tcctccgccg acgcccttgc	1728
	caaagacgcg ctggatcgtg aagcaaagtc cggcaccggc gttcctggtc aagttgctat	1788
	ccccactgc cgttcgaag ccgtatctgt ccctaccttg ggctttgctc gcctgagcaa	1848
50	gggtgtggac ttcagcggac ctgatggcga tgccaacttg gtgttctca ttgcagcacc	1908
	tgctggcggc ggcaaagagc acctgaagat cctgtccaag cttgctcgct ccttggtgaa	1968
	gaaggatttc atcaaggctc tgcaggaagc caccaccgag caggaaatcg tcgacgttgt	2028
	cgatgccgtg ctcaaccag caccaaaaac caccgagcca gctgcagctc cggctgcggc	2088
	ggcggttgct gagagtggg cggcgtcgac aagcgttact cgtatcgtgg caatcaccgc	2148
55	atgcccaacc gg	2160
	<210> 4	
	<211> 330	
	<212> PRT	
60	<213> Corynebacterium glutamicum	

<400> 4
 Met Ile Ile Thr Phe Thr Pro Asn Pro Ser Ile Asp Ser Thr Leu Ser
 1 5 10 15
 5 Leu Gly Glu Glu Leu Ser Arg Gly Ser Val Gln Arg Leu Asp Ser Val
 20 25 30
 Thr Ala Val Ala Gly Gly Lys Gly Ile Asn Val Ala His Ala Val Leu
 35 40 45
 10 Leu Ala Gly Phe Glu Thr Leu Ala Val Phe Pro Ala Gly Lys Leu Asp
 50 55 60
 15 Pro Phe Val Pro Leu Val Arg Asp Ile Gly Leu Pro Val Glu Thr Val
 65 70 75 80
 Val Ile Asn Lys Asn Val Arg Thr Asn Thr Val Thr Glu Pro Asp
 85 90 95
 20 Gly Thr Thr Thr Lys Leu Asn Gly Pro Gly Ala Pro Leu Ser Glu Gln
 100 105 110
 Lys Leu Arg Ser Leu Glu Lys Val Leu Ile Asp Ala Leu Arg Pro Glu
 115 120 125
 25 Val Thr Trp Val Val Leu Ala Gly Ser Leu Pro Pro Gly Ala Pro Val
 130 135 140
 30 Asp Trp Tyr Ala Arg Leu Thr Ala Leu Ile His Ser Ala Arg Pro Asp
 145 150 155 160
 Val Arg Val Ala Val Asp Thr Ser Asp Lys Pro Leu Met Ala Leu Gly
 165 170 175
 35 Glu Ser Leu Asp Thr Pro Gly Ala Ala Pro Asn Leu Ile Lys Pro Asn
 180 185 190
 Gly Leu Glu Leu Gly Gln Leu Ala Asn Thr Asp Gly Glu Glu Leu Glu
 195 200 205
 40 Ala Arg Ala Ala Gln Gly Asp Tyr Asp Ala Ile Ile Ala Ala Ala Asp
 210 215 220
 Val Leu Val Asn Arg Gly Ile Glu Gln Val Leu Val Thr Leu Gly Ala
 225 230 235 240
 Ala Gly Ala Val Leu Val Asn Ala Glu Gly Ala Trp Thr Ala Thr Ser
 245 250 255
 50 Pro Lys Ile Asp Val Val Ser Thr Val Gly Ala Gly Asp Cys Ala Leu
 260 265 270
 Ala Gly Phe Val Met Ala Arg Ser Gln Lys Lys Thr Leu Glu Glu Ser
 275 280 285
 55 Leu Leu Asn Ala Val Ser Tyr Gly Ser Thr Ala Ala Ser Leu Pro Gly
 290 295 300
 60 Thr Thr Ile Pro Arg Pro Asp Gln Leu Ala Thr Ala Gly Ala Thr Val
 305 310 315 320

Thr Gln Val Lys Gly Leu Lys Glu Ser Ala
325 330

5 <210> 5
<211> 27
<212> DNA
<213> Synthetic sequence

10 <220>
<221> misc_feature
<222> (1)..(27)
<223> Primer pfkB for

15 <400> 5
cttctagacc cgaccacaac tttcagg 27

20 <210> 6
<211> 29
<212> DNA
<213> Synthetic sequence

25 <220>
<221> misc_feature
<222> (1)..(29)
<223> Primer pfkB int

<400> 6
agaagcttgc caggtgtatc caagctctc 29

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

Degussa AG
Kantstr. 2

33970 Halle/Künsebeck

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
Issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: DH5alphamcr/ pXK99EmobpfbK	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 14741
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I. above was accompanied by: <input checked="" type="checkbox"/> a scientific description <input checked="" type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable).	
III. RECEIPT AND ACCEPTANCE	
International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 2002-01-11 (Date of the original deposit) ¹ .	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): <i>V. Wehls</i> Date: 2002-01-14

¹ Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.


**BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE**

INTERNATIONAL FORM

Degussa AG
Kantstr. 2

33970 Halle/Künsebeck

VIABILITY STATEMENT
issued pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. DEPOSITOR	II. IDENTIFICATION OF THE MICROORGANISM
Name: Degussa AG Kantstr. 2 Address: 33970 Halle/Künsebeck	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 14741 Date of the deposit or the transfer ¹ : 2002-01-11
III. VIABILITY STATEMENT	
The viability of the microorganism identified under II above was tested on 2002-01-11 ² . On that date, the said microorganism was <input checked="" type="checkbox"/> viable <input type="checkbox"/> no longer viable	
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED⁴	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: 2002-01-14

- ¹ Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).
- ² In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.
- ³ Mark with a cross the applicable box.
- ⁴ Fill in if the information has been requested and if the results of the test were negative.

Form DSMZ-BP/9 (sole page) 0196

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/02830

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N9/12 C12N15/54 C12P13/04 C12P13/08 C12N1/21

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBL, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	EP 1 103 613 A (DEGUSSA AG) 30 May 2001 (2001-05-30)	1,2
P,Y	See SEQ ID No. 1 the whole document	3-14
P,X	EP 1 106 622 A (DEGUSSA AG) 13 June 2001 (2001-06-13)	1,2
P,Y	see SEQ ID No. 1 the whole document	3-14
P,X	EP 1 108 790 A (KYOWA HAKKO KOGYO CO., LTD.) 20 June 2001 (2001-06-20) see SEQ ID No. 7063 and SEQ ID 7065 the whole document	1,2
	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

1 July 2002

Date of mailing of the international search report

11/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Douschan, K

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/EP 02/02830

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PATENT ABSTRACTS OF JAPAN vol. 012, no. 344 (C-528), 16 September 1988 (1988-09-16) & JP 63 102692 A (KYOWA HAKKO KOGYO CO. LTD), 7 May 1988 (1988-05-07) abstract	1-14
Y	WO 00 77172 A (AJINOMOTO CO., INC.) 21 December 2000 (2000-12-21) see the abstract	1-14

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/02830

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1103613	A	30-05-2001	DE 19956131 A1	31-05-2001
			AU 7166500 A	24-05-2001
			BR 0005543 A	07-08-2001
			CN 1297055 A	30-05-2001
			EP 1103613 A1	30-05-2001
			JP 2001186895 A	10-07-2001
			PL 344076 A1	04-06-2001
			SK 17362000 A3	08-10-2001
EP 1106622	A	13-06-2001	DE 10011922 A1	31-05-2001
			AU 7174500 A	24-05-2001
			BR 0005531 A	07-08-2001
			CN 1297054 A	30-05-2001
			EP 1106622 A2	13-06-2001
			JP 2001186896 A	10-07-2001
			PL 344073 A1	04-06-2001
			SK 17372000 A3	03-12-2001
EP 1108790	A	20-06-2001	EP 1108790 A2	20-06-2001
JP 63102692	A	07-05-1988	JP 2101579 C	22-10-1996
			JP 7121227 B	25-12-1995
WO 0077172	A	21-12-2000	AU 5106800 A	02-01-2001
			BR 0011672 A	19-03-2002
			EP 1195431 A1	10-04-2002
			WO 0077172 A1	21-12-2000

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)

acid 4WO